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012.10.0Abstract Aim: The purpose of this study was to compare the impact of incomplete revasculariza-
tion (IR) plus optimal medical therapy (OMT) to OMT alone on 1 year clinical outcomes in
patients with multivessel coronary artery disease (MVD) who were not eligible for coronary bypass
graft surgery (CABG).
Methods: This is a prospective randomized study conducted on 50 selected patients with chronic
stable angina with documented MVD and CABG was refused by the surgeon due to poor distal
vessel quality. Patients were randomized 1:1 into two groups, group (I): 25 patients were subjected
to OMT alone and group (II): 25 patients were subjected to IR plus OMT. All patients were sub-
jected to 1 year follow up.
Results: The baseline patients’ details were matched. At 1 year; death occurred slightly more in
group II (16% versus 12%; p= 1.000), ACS occurred more in the group I (32% versus 16%;
p= 0.321) while freedom from angina occurred more in group II (20% versus 4%; p= 0.189).
The OMT alone did not affect neither the level of angina class nor EF; while the IR plus OMT
markedly improved the decline in the level of angina class (p= 0.011), but it did not improve
EF signiﬁcantly (p= 0.326).
Conclusion: In patients with MVD who were not eligible for CABG; IR plus OMT was not supe-
rior to OMT alone in improving the 1 year clinical outcomes except the improvement in the level of
angina class, which could be the adopted strategy to improve the quality of life in such patients.
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021. Introduction
When treating patients with coronary artery disease (CAD),
clinicians consider whether management should be medical
therapy (MT) alone or in addition to coronary revasculariza-
tion. When revascularization is recommended, both coronary
artery bypass graft surgery (CABG) and percutaneous coro-
nary intervention (PCI) are potential options. Typically, the
treatment recommendation is based on clinical presentation,g by Elsevier B.V. All rights reserved.
58 M. Sadaka et al.severity and magnitude of ischemia, extent and distribution of
coronary anatomic disease, presence of other non-cardiac
medical conditions, and evidence of the effectiveness of each
strategy.1 Unlike CABG surgery, where most patients are com-
pletely revascularized and where complete revascularization
(CR) has been demonstrated to be associated with better
long-term outcomes, the strategy for multivessel disease pa-
tients undergoing PCI frequently involves incomplete revascu-
larization (IR). In IR, balloon angioplasty and stent placement
are performed on only some of the patients’ diseased vessels.
Reasons for not attempting all diseased vessels may include
the presence of one or more chronic total occlusions, the pres-
ence of serious medical conditions such as severe left ventricu-
lar dysfunction, severe renal impairment or the decision to
treat only the ‘‘culprit lesion’’ that is thought to be responsible
for the patient’s symptoms.2 Although multiple studies have
compared the outcomes of patients who have been completely
and incompletely revascularized with PCI, few of these are re-
cent. Most of these studies were conducted before the intro-
duction of coronary stenting, and many were conducted in
the context of randomized trials in which incompletely revas-
cularized patients were monitored more closely than they
would be under normal circumstances.3–7
The implications of the 10-year ﬁndings from MASS-II
are that revascularization, particularly with CABG, improves
the outcomes of patients with multivessel disease in compar-
ison to MT alone. To this point in time, data from individ-
ual clinical trials have not demonstrated any beneﬁt from
revascularization by CABG or PCI over optimum medical
therapy (OMT) alone in regard to decreasing the incidence
of death (total or cardiac) or fatal myocardial infarction
(MI).8,9 In fact, recommendations of appropriateness and
guideline documents have emphasized the lack of clinical
beneﬁt and have advocated against the routine application
of revascularization procedures for patients with multivessel
disease and preserved left ventricular function, except for
the relief of symptoms unresponsive to aggressive medical
therapy. Till now, no consensus about revascularization volume
in multivessel disease has been reached in the worldwide
practice.10
The recently completed Clinical Outcomes Utilizing Revas-
cularization and Aggressive Drug Evaluation (COURAGE)
Trial forms much of the basis for such a position. In this large,
multi-national investigation, an initial management strategy of
PCI combined with intensive OMT was compared to a strategy
of deferred PCI and OMT. At 5 years, COURAGE investiga-
tors found no difference in rates of death, MI, stroke, or hos-
pitalization for an acute coronary syndrome between the two
treatment groups. COURAGE patients differed, however,
from MASS-II patients, the extent of CAD was substantially
greater in MASS-II patients than those in COURAGE, a pos-
sible explanation for the differences in ﬁndings. Of note,
COURAGE did observe a beneﬁt for PCI over OMT for relief
of angina. A similar effect was seen for CABG in MASS-II.
Importantly, MASS-II also compared revascularization by
CABG to that of PCI. As noted above, however, cardiovascu-
lar therapies evolve and become more reﬁned over time.11
Although OMT, CABG, and PCI have each improved, PCI
has arguably changed the most in terms of procedural tech-
nique, intensive use of ancillary antiplatelet and anticoagulant
drugs, and stents with superior design features, including thin-ner struts and antirestenotic drug delivery. The purpose of this
study was to compare the impact of IR plus OMT to OMT
alone on 9 month clinical outcomes (death, acute coronary
syndrome (ACS) and angina class) in patients with multivessel
disease who were not eligible or refused CABG.
2. Methods
This is a prospective randomized study conducted on 50 se-
lected patients with chronic stable angina and without past his-
tory of revascularization; they have documented multivessel
coronary artery disease (MVD) by standard coronary angiog-
raphy and CABG was the only option of revascularization but
was refused by surgeon due to the poor quality of the distal
vessels. All patients had a non-viable myocardium documented
by viability studies (either dobutamine stress echocardiogra-
phy (DSE) or myocardial perfusion scintigraphy) were ex-
cluded from the study. Syntax score was calculated for all
patients. Patients were randomized 1:1 into two groups, group
(I): 25 patients were subjected to optimum medical therapy
(OMT) alone and group (II): 25 patients were subjected to
incomplete revascularization (IR) {PCI in one or two vessels
only with drug eluting stents (DES)} plus OMT. All patients
were subjected to detailed history taking, clinical evaluation,
electrocardiogram (ECG), echocardiography, and laboratory
investigations. All patients will be subjected to 1 year follow
up (FU) as regards; death, hospitalization for decompensated
heart failure, acute coronary syndrome (ACS), angina class,
ejection fraction (EF) and revascularization {target vessel
revascularization (TVR) and non target vessel revasculariza-
tion (non-TVR)}
Informed written consent was signed by every patient en-
rolled in the study after a detailed complete explanation of
the study purpose and details.
2.1. Statistical analysis
Data were analyzed using SPSS software package version
18.0 (SPSS, Chicago, IL, USA). Quantitative data were
expressed using Range, mean, standard deviation and
median while Qualitative data were expressed in frequency
and percent. Qualitative data were analyzed using the
Chi-square test also exact tests such as Fisher exact and
Monte Carlo were applied to compare different groups,
while McNemar-Bowker was used to analyze the signiﬁ-
cance between the different stages. Not normally distrib-
uted quantitative data were analyzed using the Mann
Whitney test for comparing two groups. P value was assumed
to be signiﬁcant at 0.05.3. Results
3.1. Descriptive data (Tables 1 and 2)
The baseline patients’ demographic characteristics (Table 1),
echocardiographic and angiographic details (Table 2) did not
differ substantially between the two studied groups. Also, a
high syntax score (P33) was almost found in majority of
patients in both groups (23 patients in the OMT group and
24 patients in the IR plus OMT group; p= 1.000).
Table 1 Baseline demographic data of both groups.
OMT group (n= 25) IR plus OMT group (n= 25) p Value
No. (%) No. (%)
Age, (years) 65.24 ± 10.38 65.72 ± 9.11 p= 0.863
Sex
Male 18 72.0 17 68.0 p= 0.758
Female 7 28.0 8 32.0
Smoking
Current smoker 8 32.0 2 8.0 p= 0.105
Ex-smoker 10 40.0 14 56.0
Diabetes mellitus 14 56.0 18 72.0 p= 0.239
Hypertension 17 68.0 16 64.0 p= 0.765
Dyslipidemia 19 76.0 17 68.0 p= 0.529
Previous ACS 20 80.0 17 68.0 p= 0.333
Previous Stoke 2 8.0 2 8.0 p= 1.000
Renal impairment 7 28.0 6 24.0 p= 1.000
Peripheral arterial disease 5 20.0 2 8.0 p= 0.417
*COPD 7 28.0 3 12.0 p= 0.289
**Anemia 5 20.0 7 28.0 p= 0.508
Angina class
I 2 8.0 2 8.0 p= 0.756
II 12 48.0 8 32.0
III 10 40.0 14 56.0
IV 1 4.0 1 4.0
* COPD is deﬁned as chronic obstructive pulmonary disease documented by pulmonary function tests.
** Anemia is deﬁned as hemoglobin less than 10 grams.
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As regards the medications prescribed to the patients, they did
not differ substantially between the two groups except for the
clopidogrel (plavix) which was prescribed more frequent in the
IR plus OMT group than in the medical group (100% vs.
76.0%, p= 0.022).
In the IR plus OMTgroup, as regards the PCI procedure, the
selected vessel was based upon the ischemic burden judged by
the viability study also by the feasibility to angioplasty. PCI of
the LM was done in 4% of patients, LAD in 52%, D1 in 8%,
LCX in 36% and RCA in 36% of patients. One vessel was at-
tempted in 64% of patients and two vessels were attempted in
36% of patients. The procedural success rate was 96%.
3.3. One year follow up: (Table 4)
All patients were followed up for 1 year; death occurred
slightly more in the IR plus OMT group (16% versus 12%;
p= 1.000), hospitalization for decompensated CHF occurred
more in the OMT group (28% versus 12%; p= 0.289), ACS
occurred more in the OMT group (32% versus 16%;
p= 0.321) while freedom from angina occurred more in the
IR plus OMT group (20% versus 4%; p = 0.189); however
all these differences were not statistically signiﬁcant. In the
IR plus OMT group; TVR occurred in 16% of patients while
non-TVR in 32% of patients.
3.4. The effect of OMT alone versus IR plus OMT on EF and
angina class
The OMT alone did not affect neither the level of angina class
nor EF; while the IR plus OMT markedly improved thedecline in the level of angina class with statistically signiﬁcant
difference (p= 0.011), but it did not improve EF signiﬁcantly
(p= 0.326), as demonstrated in (Table 5).
A case example of male patient 67 years old with diffuse
distal LAD disease, subtotal occlusion of diffuse OM1 and dif-
fuse mid to distal RCA disease with class III angina,
EF = 50%. The patient was refused by the surgeon due to
poor distal vessel quality. The patient was then subjected to
PCI RCA with 2 DES and a good ﬁnal result was obtained
with improvement in his angina class to class I during 1 year
of FU as demonstrated in (Fig. 1).
Another case example of female patient 74 years old with
angina class IV with ostial LM 30%, diffuse disease of the
LAD, diffuse disease of LCX and critical proximal RCA le-
sion, EF = 30%. The patient was refused by the surgeon
due to very poor vessel quality and poor EF. The patient
was then subjected to PCI of proximal RCA with 1 DES
and a good ﬁnal result was obtained but with a partial
improvement in the level of angina class to class II, the patient
died at home at 8 months of FU as demonstrated in (Fig. 2).
4. Discussion
In MVD patients, when CABG the only option of revascular-
ization was refused by the surgeon due to the poor quality of
the distal vessels, the option of complete revascularization by
PCI sometimes is not applicable to all patients for many rea-
sons including unsuitable anatomy for PCI, poor LV function,
renal impairment and in some patients for ﬁnancial issues.
Many studies had investigated the option of incomplete revas-
cularization but with conﬂicting results and till this moment
both American and European guidelines of PCI are not clear
in this particular group of patients.
Table 2 Echocardiographic and angiographic details of both groups.
OMT group (n= 25) IR plus OMT group (n= 25) p Value
No. (%) No. (%)
Echocardiography
Ejection fraction p= 0.534
Range 30.0  62.0 25.0  79.0
Mean 46.36 ± 9.69 48.48 ± 13.86
Median 48.0 48.0
Mitral regurgitation 13 52.0 9 36.0 p= 0.254
Angiography
LM 8 32.0 5 20.0 p= 0.333
LAD 25 100.0 25 100.0 –
D1 18 72.0 14 56.0 p= 0.239
LCX 19 76.0 23 92.0 p= 0.247
RCA 20 80.0 22 88.0 p= 0.702
Syntax score
Range 28.0  57.0 29.0  52.0
Mean 40.96 ± 7.06 40.36 ± 5.92 p= 0.746
Median 40.0 39.0
High syntax score (P33) 23 92.0 24 96.0 p= 1.000
Table 3 Treatment details of both groups.
OMT group (n= 25) IR plus OMT group (n= 25) p Value
No. % No. %
Medical treatment
BBS 17 68.0 19 76.0 p= 0.754
Ivabradine 7 28.0 5 20.0 p= 0.508
ACE-I or ARBS 22 88.0 16 64.0 p= 0.095
ASA 25 100.0 25 100.0 –
Clopidogrel 19 76.0 25 100.0 p= 0.022*
CCBs 3 12.0 3 12.0 p= 1.000
Statins 25 100.0 23 92.0 p= 0.490
Nitrates 24 96.0 21 84.0 p= 0.349
Digoxin 10 40.0 6 24.0 p= 0.225
Diuretics 12 48.0 15 60.0 p= 0.571
Nicorandil 3 12.0 0 0.0 p= 0.235
Trimedazidine 16 64.0 21 84.0 p= 0.196
PCI
LM – 1 4.0 –
LAD 13 52.0
D1 2 8.0
LCX 9 36.0
RCA 9 36.0
No. of vessels attempted
One – 16 64.0 –
Two 9 36.0
* Statistically signiﬁcant at p 6 0.05.
60 M. Sadaka et al.The mean age of our studied patients in both groups was
65 years while male gender was more predominant around
two third of the cases. Kim et al.12 studied a total of 1914 con-
secutively enrolled patients with MVD undergoing drug-elut-
ing stent implantation (1400 patients) or CABG (514
patients). The outcomes of patients undergoing CR were com-
pared with those undergoing IR. Hannan et al.2 studied 11,294
stent patients with MVD undergoing either IR or CR in 39hospitals. The mean age and male gender predominance in
both studies were comparable to our patients.
In our study the one year follow up revealed; death oc-
curred slightly more in the IR plus OMT group (16% versus
12%; p= 1.000), hospitalization for decompensated CHF oc-
curred more in the OMT group (28% versus 12%; p= 0.289),
ACS occurred more in the OMT group (32% versus 16%;
p= 0.321) while freedom from angina occurred more in the
Table 4 One year follow up of both groups.
OMT group (n= 25) IR plus OMT group (n= 25) p Value
No. % No. %
Death 3 12.0 4 16.0 p= 1.000
Hospitalization for decompensated CHF 7 28.0 3 12.0 p= 0.289
ACS 8 32.0 4 16.0 p= 0.321
Angina free 1 4.0 5 20.0 p= 0.189
Angina class
I 10 40.0 12 48.0 p= 0.461
II 11 44.0 7 28.0
III 3 12.0 1 4.0
IV 0 0.0 0 0.0
Ejection fraction
Range 30.0  60.0 20.0  75.0 p= 0.343
Mean 44.44 ± 10.17 47.76 ± 14.02
Median 47.0 50.0
Revascularization
TVR – 4 16.0 –
Non TVR 8 32.0
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these differences were not statistically signiﬁcant. The OMT
alone did not affect neither the level of angina class nor EF;
while the IR plus OMT markedly improved the decline in
the level of angina class with a statistically signiﬁcant differ-
ence (p= 0.011), but it did not improve EF signiﬁcantly
(p= 0.326).
Nikolsky et al.13 examined 658 consecutive diabetic patients,
MVD was present in 352 patients (94 CR patients and 258 IRTable 5 Angina class and EF at baseline and 1 year follow up in t
Baseline
No. %
OMT
Angina class
0 0 0.
I 2 8.
II 12 48.
III 10 40.
IV 1 4.
EF
Range 30.0 – 62.0
Mean ± SD 46.36 ± 9.69
Median 48.0
IR plus OMT
Angina class
0 0 0.
I 2 8.
II 8 32.
III 14 56.
IV 1 4.
EF
Range 25.0  79.0
Mean ± SD 48.48 ± 13.86
Median 48.0
* Statistically signiﬁcant at p 6 0.05.patients) who underwent PCI and they found that CR patients
had a signiﬁcantly higher survival rate at 5 years (94.5% vs.
83.0%, p= 0.001). Also, the rate ofMI-free survival was signif-
icantly higher for CR patients (92.9% vs. 79.9%, respectively).
In a single center observational study,Kalarus et al.14 found that
among PCI patients with acuteMI, remote mortality (18.5% vs.
7.2%, p= 0.001) and major adverse cardiac event (53.1% vs.
24.3%, p = 0.001) rates were both higher for IR patients than
for CR patients. Hannan et al.2 found that incompletehe two studied groups.
1 year FU p Value
No. %
0 10 40.0 p= 0.249
0 11 44.0
0 3 12.0
0 0 0.0
0 0 0.0
30.0 – 60.0 p= 0.058
44.44 ± 10.17
47.0
0 12 48.0 p= 0.011*
0 7 28.0
0 1 4.0
0 0 0.0
0 0 0.0
20.0  75.0 p= 0.326
47.76 ± 14.02
50.0
Figure 1 Case example of male patient 67 years old with IR plus OMT.
62 M. Sadaka et al.revascularization was associated with signiﬁcantly higher
18-month mortality (adjusted HR: 1.23, 95% CI: 1.04 to 1.45)
and higher 18-month MI/mortality (adjusted HR: 1.27, 95%
CI: 1.09 to 1.47). Kim et al.12 observed a borderline signiﬁcant
association between multivessel IR and clinical prognosis.
WhenMVDwas not revascularized, the risk of 5-year MACCE
was signiﬁcantly elevated in either PCI or CABG patients. A
previous radionuclide study showed that revascularization for
more than moderate ischemia (P 10% of total myocardium)
with the use of a myocardial perfusion scan improved the
survival.15 Similarly, Shaw et al.16 in the Clinical Outcomes
Utilizing Revascularization and Aggressive Drug Evaluation(COURAGE) trial, which compared OMT with prompt PCI
for stable patients, patients with ischemia reduction after
treatment, based on pretreatment and post treatment myocar-
dial perfusion scans, revealed that those patients tended to have
lower risks of death and MI. Thus, the association between CR
and clinical outcomes in previous studies may be indirectly
related to the extensive reduction of ischemia and not directly
related to anatomic revascularization.17,18 Also, Tamburino et
al.19 studied 508 patients: 212 (41.7%) and 296 (58.3%) had
CR and IR, respectively. The median follow-up was 27 months.
CR was associated with better outcomes for components of the
composite endpoint: 0.37 (0.15–0.92, p= 0.03) for cardiac
Figure 2 Case example of female patient 74 years old with IR plus OMT.
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death or MI and 0.45 (0.29–0.69, p= 0.0003) for any repeat
revascularization.
In contrary some other studies advocated the IR strategy
demonstrating favorable outcomes. Mariani et al.20 studied
208 consecutive patients (171 men) with MVD. Mean age of
the group was 63.8 ± 10.3 years (range, 31–91). Complete
and incomplete revascularization was achieved in 49 and 159
patients, at 1-year follow-up, 11.3% and 11.5% of patients
with complete and incomplete revascularization, respectively,
had MACE. These results indicate that the strategy of incom-
plete revascularization in unstable angina patients with MVD
does not expose them to a higher risk of death or other majorischemic events in comparison to those undergoing complete
revascularization. Same data reported by Bourassa et al.21
intended incomplete angioplasty revascularization in non-
diabetic patients with MVD who are candidates for both angi-
oplasty and CABG does not compromise long-term survival;
however, a subsequent need for CABG may be increased with
this strategy while the risk of long-term MI is also increased.
Rossi et al.22 studied 165 octogenarians, 73 elderly patients
(44%) underwent CR and 92 (56%) IR. Major in-hospital car-
diac events were similar in the two subgroups. At 1-year fol-
low-up 65% of patients in the CR and 68% in the IR group
(p= ns) referred improvement in angina status and quality
of life. They concluded that, current PCI coronary techniques
64 M. Sadaka et al.are safe and effective in octogenarians. PCI limited to the cul-
prit lesion may sufﬁce in most patients, with favorable clinical
outcome at 1 year.
By comparing our results to the previous studies; despite
the majority of data defers the strategy of IR and recom-
mended total revascularization, it remains that patient with
MVD was refused by the surgeon as a common problem every
day in catheter laboratory. We found that the policy of IR plus
OMT in patients is superior to OMT alone in relieving angina
but has no impact on long term survival or freedom from MI.
The outcomes of our study are more or less different from
many reported previous studies; this could be explained by
the small number of patients recruited for the study, different
patients’ subsets and the relative short duration of follow up.
May be further studies, testing the IR guided by myocardial
perfusion scintigraphy for detecting the ischemic burden, could
have an impact on long term MACE plus angina relief in those
particular group of patients.5. Conclusion
In patients with MVD who were not eligible for CABG; IR
plus OMT was not superior to OMT alone in improving the
1year clinical outcomes except the improvement in the level
of angina class, which could be the adopted strategy to improve
the quality of life in such patients but with close follow up.6. Study limitations
There are a few caveats to the study. First, it is single center
study. Second, the small number of the patients included in
this study. Third, the undermined ischemic burden before the
strategy of incomplete revascularization. Fourth, the relative
short duration of follow-up.References
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